  Since the rise of the SARS-CoV-2 pandemic in the winter of 2019, the need for
an affordable and efficient drug has not yet been met. Leveraging its unique,
fast and precise binding free energy prediction technology, Aqemia screened and
ranked FDA-approved molecules against the 3ClPro protein. This protease is key
to the post-translational modification of two polyproteins produced by the
viral genome. We propose in our top 10 predicted molecules some drugs or
prodrugs that could be repurposed and used in the treatment of COVID cases.
